Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208.

Literature DB >> 24724581

EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208.

Abstract

LINKED ARTICLE: This article is a Commentary on Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195-5208. doi: 10.1111/bph.12669.

Entities: Chemical

Keywords: EPH receptors; angiogenesis inhibitors; cancer; ephrins

Year: 2015 PMID： 24724581 PMCID： PMC4562520 DOI： 10.1111/bph.12718

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

11 in total

Review 1. Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Authors: Victor Moreno Garcia; Bristi Basu; L Rhoda Molife; Stan B Kaye
Journal: Clin Cancer Res Date: 2012-04-30 Impact factor: 12.531

2. Inhibition of retinal neovascularization by soluble EphA2 receptor.

Authors: Jin Chen; Donna Hicks; Dana Brantley-Sieders; Nikki Cheng; Gary W McCollum; Xiang Qi-Werdich; John Penn
Journal: Exp Eye Res Date: 2005-12-15 Impact factor: 3.467

Review 3. Therapeutic targeting of EPH receptors and their ligands.

Authors: Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal: Nat Rev Drug Discov Date: 2014-01 Impact factor: 84.694

Review 4. Eph-ephrin bidirectional signaling in physiology and disease.

Authors: Elena B Pasquale
Journal: Cell Date: 2008-04-04 Impact factor: 41.582

5. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.

Authors: Suphansa Sawamiphak; Sascha Seidel; Clara L Essmann; George A Wilkinson; Mara E Pitulescu; Till Acker; Amparo Acker-Palmer
Journal: Nature Date: 2010-05-05 Impact factor: 49.962

Review 6. Paradoxes of the EphB4 receptor in cancer.

Authors: Nicole K Noren; Elena B Pasquale
Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701

Review 7. Angiogenesis: an organizing principle for drug discovery?

Authors: Judah Folkman
Journal: Nat Rev Drug Discov Date: 2007-04 Impact factor: 84.694

8. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Authors: I Hassan-Mohamed; C Giorgio; M Incerti; S Russo; D Pala; E B Pasquale; I Zanotti; P Vicini; E Barocelli; S Rivara; M Mor; A Lodola; M Tognolini
Journal: Br J Pharmacol Date: 2014-08-28 Impact factor: 8.739

Review 9. VEGF targets the tumour cell.

Authors: Hira Lal Goel; Arthur M Mercurio
Journal: Nat Rev Cancer Date: 2013-12 Impact factor: 60.716

10. The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.

Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739

1 in total

1. Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors: Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal: ACS Med Chem Lett Date: 2014-09-29 Impact factor: 4.345

1 in total